Clinical Characteristics, Treatment and Survival Outcomes in Malignant Mesothelioma: Eighteen Years' Experience in Turkey |
Berk, Serdar
(Department of Chest Diseases, Faculty of Medicine, Cumhuriyet University)
Dogan, Omer Tamer (Department of Chest Diseases, Faculty of Medicine, Cumhuriyet University) Kilickap, Saadettin (Department of Medical Oncology, Faculty of Medicine, Cumhuriyet University) Epozturk, Kursat (Department of Chest Diseases, Faculty of Medicine, Cumhuriyet University) Akkurt, Ibrahim (Department of Chest Diseases, Faculty of Medicine, Cumhuriyet University) Seyfikli, Zehra (Department of Chest Diseases, Faculty of Medicine, Cumhuriyet University) |
1 | Adams RF, Gray W, Davies RJ, Gleeson FV (2001). Percutaneous image-guided cutting needle biopsy of the pleura in the diagnosis of malignant mesothelioma. Chest, 120, 1798-802. DOI |
2 | Al-Shimemeri AA, Al-Ghadeer HM, Giridhar HR (2003). Diagnostic yield of closed pleural biopsy in exudative pleural effusion. Saudi Med J, 24, 282-6. |
3 | Beauchamp HD, Kundra NK, Aranson R, Chong F, MacDonnell KF (1992). The role of closed pleural needle biopsy in the diagnosis of malignant mesothelioma of the pleura. Chest, 102, 1110-2. DOI |
4 | Bianchi C, Brollo A, Ramani L, Bianchi T, Giarelli L (2001). Asbestos exposure in malignant mesothelioma of the pleura: a survey of 557 cases. Ind Hlth, 39, 161-7. DOI |
5 | Bianchi C, Bianchi T (2007). Malignant mesothelioma: global incidence and relationship with asbestos. Ind Hlth, 45, 379-87. DOI |
6 | Chakrabarti B, Ryland I, Sheard J, Warburton CJ, Earis JE (2006). The role of Abrams percutaneous pleural biopsy in the investigation of exudative pleural effusions. Chest, 129, 1549-55. DOI ScienceOn |
7 | Herndon JE, Green MR, Chahinian AP, et al (1998). Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest, 113, 723-31. DOI ScienceOn |
8 | Hughes RS (2005). Malignant pleural mesothelioma. Am J Med Sci, 329, 29-44. DOI |
9 | Ismail-Khan R, Robinson LA, Williams CC Jr, et al (2006). Malignant pleural mesothelioma: a comprehensive review. Cancer Control, 13, 255-63. DOI |
10 | Law MR, Gregor A, Hodson ME, Bloom HJ, Turner-Warwick M (1984). Malignant mesothelioma of the pleura: a study of 52 treated and 64 untreated patients. Thorax, 39, 255-9. DOI |
11 | Lee CW, Murray N, Anderson H, Rao SC, Bishop W (2009). Outcomes with first-line platinum-based combination chemotherapy for malignant pleural mesothelioma: a review of practice in British Columbia. Lung Cancer, 64, 308-13. DOI |
12 | Marinaccio A, Binazzi A, Cauzillo G, et al (2007). Analysis of latency time and its determinants in asbestos-related malignant mesothelioma cases of the Italian register. Eur J Cancer, 43, 2722-8. DOI |
13 | Metintas M, Hillerdal G, Metintas S (1999). Malignant mesothelioma due to environmental exposure to erionite: follow-up of a Turkish emigrant cohort. Eur Respir J, 13, 523-6. DOI |
14 | Metintas M, Hillerdal G, Metintas S, Dumortier P (2010). Endemic malignant mesothelioma: exposure to erionite is more important than genetic factors. Arch Environ Occup Hlth, 65, 86-93. DOI |
15 | Moore AJ, Parker RJ, Wiggins J (2008). Malignant mesothelioma. Orphanet J Rare Dis, 3, 34. DOI |
16 | Pistolessi M, Rusthoven J (2004). A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. Chest, 126, 1318-29. DOI ScienceOn |
17 | MTA (General Directorate of Mineral Research and Exploration). Mineral map of Sivas. http://www.mta.gov.tr/v2.0/turkiye_maden/il_maden/pdf_2010/sivas.pdf [Last accessed in 31.10.2012]. |
18 | Muers MF, Stephens RJ, Fisher P, et al (2008). Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. Lancet, 371, 1685-94. DOI |
19 | Pasetto R, Comba P, Marconi A (2005). Mesothelioma associated with environmental exposures. Med Lav, 96, 330-7. |
20 | Rahman NM, Gleeson FV (2008). Image-guided pleural biopsy. Curr Opin Pulm Med, 14, 331-6. DOI |
21 | Renshaw AA, Dean BR, Antman KH, Sugarbaker DJ, Cibas ES (1997). The role of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma. Chest, 111, 106-9. DOI ScienceOn |
22 | Rusch VW, Rosenzweig K, Venkatraman E, et al (2001). A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg, 122, 788-95. DOI |
23 | Ruth VS, Baas P, Zoetmulder FA (2003). Surgical treatment of malignant pleural mesothelioma. A review. Chest, 123, 551-61. DOI |
24 | Scherpereel A, Astoul P, Baas P, et al (2010). Guideline of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur Respir J, 35, 479-95. DOI ScienceOn |
25 | Sterman DH, Litzky LA, Albelda SM (2008). Malignant mesothelioma and other primary pleural tumors. In: Fishman AP, Elias JA (eds.) Fishman's Pulmonary Diseases and Disorders, 4th ed. McGraw-Hill, Philadelphia, pp1535-52. |
26 | Senyigit A, Coskunel M, Topcu F, Isik R, Babayigit C. (2000). Malignant Pleural Mesothelioma: Evaluation of Clinical, Radiological and Histological Features in 136 Cases. Tuberculosis and Thorax, 48, 26-34. |
27 | Skammeritz E, Omland LH, Johansen JP, Omland O (2011). Asbestos exposure and survival in malignant mesothelioma: a description of 122 consecutive cases at an occupational clinic. Int J Occup Environ Med, 2, 224-36. |
28 | Stahel RA, Weder W, Lievens Y, Felip E; ESMO Guideline Working Group (2010). Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 21, 126-8. DOI |
29 | Sugarbaker DJ, Flores RM, Jaklitsch MT, et al (1999). Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg, 117, 54-65. DOI |
30 | van Thiel ER, Surmont VF, van Meerbeeck JP. Malignant pleural mesothelioma: when is radiation therapy indicated? Expert Rev Anticancer Ther, 11, 551-60. |
31 | Vogelzang NJ, Rusthoven JJ, Symanowski J, et al (2003). Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol, 21, 2636-44. DOI ScienceOn |
32 | Walters J, Maskell NA (2011). Biopsy techniques for the diagnosis of mesothelioma. Recent Results Cancer Res, 189, 45-5. DOI |
33 | Wang ZJ, Reddy GP, Gotway MB, et al (2004). Malignant pleural mesothelioma: evaluation with CT, MR imaging, and PET. Radiographics, 24, 105-19. DOI ScienceOn |
34 | Yilmaz UM, Utkaner G, Yalniz E, Kumcuoglu Z (1998). Computed tomographic findings of environmental asbestosrelated malignant pleural mesothelioma. Respirology, 3, 33-8. DOI |
![]() |